{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:54:54Z","timestamp":1779108894333,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.annder.2024.103336","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T20:34:03Z","timestamp":1734554043000},"page":"103336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of dupilumab in chronic prurigo: A multicentre retrospective study"],"prefix":"10.1016","volume":"152","author":[{"given":"M.","family":"Gael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schoeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-C.","family":"Bursztejn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103336_b0005","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103336_b0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2019.07.022","article-title":"Diagnostic and treatment algorithm for chronic nodular prurigo","volume":"82","author":"St\u00e4nder","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0015","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1111\/jdv.17333","article-title":"Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases","volume":"35","author":"Misery","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103336_b0020","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis","volume":"83","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients: Prurigo aetiology","volume":"27","author":"Iking","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103336_b0030","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/j.pain.0000000000001220","article-title":"Alloknesis and hyperknesis \u2013 mechanisms, assessment methodology, and clinical implications of itch sensitization","volume":"159","author":"Andersen","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.annder.2024.103336_b0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ana.25912","article-title":"Keratinocytes communicate with sensory neurons via synaptic-like contacts","volume":"88","author":"Talagas","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.annder.2024.103336_b0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.annder.2024.103336_b0045","first-page":"5","article-title":"Chronic Pruritus: A review of neurophysiology and associated immune neuromodulatory treatments","volume":"23","author":"Patel","year":"2018","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.annder.2024.103336_b0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/ejd.2010.1196","article-title":"Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31in skin lesions of subacute and chronic forms of prurigo","volume":"21","author":"Park","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0055","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","article-title":"Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization","volume":"141","author":"Belzberg","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2018.11.007","article-title":"Current treatment strategies in refractory chronic pruritus","volume":"46","author":"Pereira","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.annder.2024.103336_b0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.reval.2019.01.009","article-title":"[Prurigo chronique. Nouvelle nosologie et prise en charge th\u00e9rapeutique.]","volume":"59","author":"Misery","year":"2019","journal-title":"Rev Fr Allergol."},{"key":"10.1016\/j.annder.2024.103336_b0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jdv.15145","article-title":"The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries","volume":"33","author":"Brenaut","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103336_b0075","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/jdv.16696","article-title":"The impact of prurigo nodularis on sleep disturbance and related impact: a systematic review","volume":"34","author":"Gwillim","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103336_b0080","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","article-title":"The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis","volume":"313","author":"Janmohamed","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.annder.2024.103336_b0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2024.103336_b0090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bjd.15905","article-title":"Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial","volume":"178","author":"Tsianakas","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.annder.2024.103336_b0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.annder.2024.103336_b0105","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/jdv.18221","article-title":"Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors","volume":"36","author":"Gael","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103336_b0110","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamadermatol.2020.3071","article-title":"Validation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: A secondary analysis of a randomized clinical trial","volume":"156","author":"Kimel","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0115","unstructured":"Sanofi. January 19, 2022. Second positive Phase 3 Dupixent\u00ae (dupilumab) trial confirms significant improvements for patients with prurigo nodularis. [Press release] https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-01-19-06-00-00-2368986."},{"key":"10.1016\/j.annder.2024.103336_b0120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2024.103336_b0125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000246715","article-title":"Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic","volume":"190","author":"Tanaka","year":"1995","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2024.103336_b0130","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211002979","article-title":"Nomenclature and clinical phenotypes of atopic dermatitis","volume":"12","author":"Girolomoni","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.annder.2024.103336_b0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103336_b0140","unstructured":"Sanofi. October 22, 2021. Dupixent\u00ae (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease. [Press release] https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-10-22-05-00-00-2318876."},{"key":"10.1016\/j.annder.2024.103336_b0145","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/jdv.18327","article-title":"Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology","volume":"36","author":"Ahn","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:31:43Z","timestamp":1741901503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0151963824000929"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103336","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of dupilumab in chronic prurigo: A multicentre retrospective study","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103336"}}